Schneider, Susan

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 3,522

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 858

Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results

Kaiser, P. K., Brown, D. M., Zhang, K., Hudson, H. L., Holz, F. G., Shapiro, H., Schneider, S., & Acharya, N. R. (2007) · American Journal of Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 361

Population-Based Incidence of Uveal Melanoma in Various Races and Ethnic Groups

Hu, D.-N., Yu, G.-P., McCormick, S. A., Schneider, S., & Finger, P. T. (2005) · American Journal of Ophthalmology

Ocular Oncology and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 238

Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration

Callanan, D., Kunimoto, D., Maturi, R. K., Patel, S. S., Staurenghi, G., Wolf, S., Cheetham, J. K., Hohman, T. C., Kim, K., López, F. J., et al. (2018) · Journal of Ocular Pharmacology and Therapeutics

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 73